-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca's Trixeo Aerosphere Wins EU Approval for Asthma Treatment

MT Newswires·09/23/2026 02:26:13
Listen to the news
02:26 AM EDT, 09/23/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Wednesday it secured the European Union's approval for its fixed-dose triple-combination Trixeo Aerosphere as a maintenance treatment for asthma patients aged 12 and older. The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use and is supported by data from two late-stage trials. In the studies, Trixeo delivered statistically significant improvements in lung function over a combination of a medium-dose inhaled corticosteroid and long-acting beta2-agonist. Trixeo is approved for asthma treatment in the US and Japan and is under regulatory review in China and other markets.